

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



SB 204990

Item No. 15245

CAS Registry No.: 154566-12-8

Formal Name: (3R,5S)-rel-5-[6-(2,4-dichlorophenyl)hexyl]

tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid


MF: C₁₈H₂₂Cl₂O₅

389.3 FW: **Purity:** ≥95%

 λ_{max} : 219 nm A crystalline solid UV/Vis.: Supplied as:

Storage: -20°C Stability: ≥2 vears

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

SB 204990 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 204990 in the solvent of choice. SB 204990 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of SB 204990 in these solvents is approximately 1, 20, and 30 mg/ml, respectively.

SB 204990 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 204990 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SB 204990 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SB 204990 is a cell-permeable prodrug form of SB 201076, an inhibitor of ATP citrate lyase. 1 SB 204990 inhibits fatty acid and cholesterol synthesis in HepG2 cells in a concentration-dependent manner. Oral administration of SB 204990 (25 mg/kg) reduces plasma levels of the lipoproteins VLDL, LDL, and HDL by 21, 40, and 22%, respectively, in dogs. It also reduces VLDL synthesis and plasma cholesterol and triglyceride levels in rats in a dose-dependent manner.

Reference

1. Pearce, N.J., Yates, J.W., Berkhout, T.A., et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 334(Pt 1), 113-119 (1998).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/21/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM